Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 320Leukemia, Myeloid, Acute 266Multiple Myeloma 227Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 202Neoplasms 196Lymphoma 191Colorectal Neoplasms 184Melanoma 179Leukemia 170Recurrence 164Pancreatic Neoplasms 163Precursor Cell Lymphoblastic Leukemia-Lymphoma 160Lung Neoplasms 150Glioblastoma 134Neoplasm Metastasis 132Lymphoma, Non-Hodgkin 128Ovarian Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 120Myelodysplastic Syndromes 117Lymphoma, Large B-Cell, Diffuse 110Lymphoma, Mantle-Cell 108Carcinoma, Hepatocellular 103Lymphoma, Follicular 99Stomach Neoplasms 96Carcinoma, Renal Cell 89Hodgkin Disease 88Brain Neoplasms 88Sarcoma 84Burkitt Lymphoma 75

Interventions

Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Mucopolysaccharidosis I × Clear all
NCT02437253 2017-09-15

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase 1/2 Completed
2 enrolled 10 charts

Inflammation, Mucopolysaccharidosis I, Mucopolysaccharidoses, Mucopolysaccharidosis VI, Mucopolysaccharidosis II

Data powered by HemOnc (CC BY 4.0) Colophon âš¡